Gene therapies: The challenge of super-high-cost treatments and how to pay for them

Regenerative Medicine

Volumn 11, Issue 4, 2016, Pages 381-393

  Carr, David R ^a   Bradshaw, Steven E ^a  

^a Valid Insight   (United Kingdom)

Author keywords

annuity; gene therapy; Glybera; market access; orphan; pay for performance; payment models; policy; rare disease; reimbursement; super high cost

Indexed keywords

BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FUNDING; GENE THERAPY; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; MARKETING; PATENT; PRIORITY JOURNAL; RARE DISEASE; REIMBURSEMENT; REVIEW; GENETICS; HEALTH CARE POLICY; RARE DISEASES; STANDARDS;

GENETIC THERAPY; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; RARE DISEASES; REIMBURSEMENT, INCENTIVE;

EID: 84974577177     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme-2016-0010     Document Type: Review

References (55)

1. JØrgensen J, Kefalas P. Reimbursement of licensed cell and gene therapies across the major European healthcare markets. J. Mark. Access Health Policy 3, 29321 (2015). assessed and reimbursed across France, Germany, Italy, Spain and the UK.
2. Kitamura M. World's most expensive medicine: is it worth the price? Bloomberg Business (2015). www.bloomberg.com/news/articles
3. New drugs online report for alipogene tiparvovec. UK Medicines Information (2015). www.ukmi.nhs.uk/applications/ndo
4. Brunzell JD. Familial lipoprotein lipase deficiency. Gene Reviews (2014). www.ncbi.nlm.nih.gov/books/NBK1308/
5. Taylor NP. Uni Qure abandons ambition to win FDA approval for 1.1M gene therapy. Fierce Biotech (2015). www.fiercebiotech.com/story
6. About rare diseases. Rare Disease UK (2015). www.raredisease.org.uk/about-rare-diseases.htm
7. Farrell PM. The prevalence of cystic fibrosis in the European Union. J. Cyst. Fibros. 7(5), 450-453 (2008).
8. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet. J. Rare Dis. 6, 42 (2011).
9. Messori A, Cicchetti A, Patregani L. Orphan drugs. Relating price determination to disease prevalence. BMJ 341 c4615 (2010).
10. Hyry HI, Manuel J, Cox TM, Roos JC. Compassionate use of orphan drugs. Orphanet. J. Rare Dis. 10, 100 (2015).
11. Forman J, Taruscio D, Llera VA et al. The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 101(8), 805-807 (2012).
12. Genane C, Marinoni G, Reinaud F, Ando G. Impact of indication extensions on pharmaceutical prices. Value Health 16(7), A455 (2013).
13. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Issues surrounding orphan disease and orphan drug policies in Europe. Appl. Health Econ. Health Policy 8(5), 343-350 (2010).
14. Kanavos P, Nicod E. What is wrong with orphan drug policies? Suggestions for ways forward. Value Health 15(8), 1182-1184 (2012).
15. Stewart M, Loftus J, Lenderking WR et al. Characterizing disease burden in an ultra-rare disease in the United States: transthyretin (TTR) amyloidosis patients & caregivers. Value Health 16(7), A386 (2013).
16. Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics 33(3), 255-269 (2015).
17. Murphy J. Patent term extensions and market exclusivity. Strategem Intellectual Property Management (2015). www.stratagemipm.co.uk/articles/2015
18. Barkholt L. Regulatory developments for advanced therapy medicinal products (ATMPs): how to navigate the European regulatory framework? Presented at: Regenerative Medicine Translation - a Pathway into Clinical Practice. London, UK, 10 December 2014.
19. Bach P. Cancer: Unpronounceable drugs, incomprehensible prices. Forbes (2014). www.forbes.com/sites/matthewherper
20. The Editorial Board. Costly hepatitis C drugs for everyone? New York Times (2015). www.nytimes.com/2015/09/02/opinion
21. Experts in Chronic Myeloid L. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121(22), 4439-4442 (2013).
22. Yla-Herttuala S. Glybera's second act: the curtain rises on the high cost of therapy. Mol. Ther. 23(2), 217-218 (2015).
23. Epstein J. Citing Shkreli, Clinton targets drug speculators. Bloomberg Politics (2015). www.bloomberg.com/politics/articles
24. Eculizumab for treating atypical haemolytic uraemic syndrome, (NICE) (2015). www.nice.org.uk/guidance/hst1
25. Elosulfase alfa for treating mucopolysaccharidosis type IVa, (NICE) (2015). www.nice.org.uk/guidance/hst2
26. Brennan TA, Wilson JM. The special case of gene therapy pricing. Nat. Biotechnol. 32(9), 874-876 (2014).
27. Bentley TS, Hanson SG. US organ and tissue transplant cost estimates and discussion, Milliman (2014). www.milliman.com/uploadedFiles/insight
28. Touchot N, Flume M. The payers' perspective on gene therapies. Nat. Biotechnol. 33(9), 902-904 (2015).
29. Bambha K, Kim WR. Liver transplantation is effective, but is it cost-effective? Liver Transpl. 9(12), 1308-1311 (2003).
30. O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA 310(13), 1343-1344 (2013).
31. Jaroslawski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv. Res. 11, 259 (2011).
32. Navarria A, Drago V, Gozzo L et al. Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure. Value Health 18(1), 131-136 (2015).
33. Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet. J. Rare Dis. 9, 62 (2014).
34. Aballea S, Toumi M, Vataire AL, Millier A, Lamure M. Quantitative analysis of the influence of disease and product characteristics on orphan drug prices in Europe. Value Health 13(3), A82 (2010).
35. Simon-Kucher & Partners. National payers in Spain seek novel agreements to reach P&R decisions for new drugs. Healthcare Insights 7(3), 6-8 (2013).
36. Crabb N. Evaluation and reimbursement of regenerative medicines and cell therapies. Presented at: Regenerative Medicine Translation - a Pathway into Clinical Practice. London, UK, 10 December 2014.
37. Van Der Vossen R. Marketing authorisations under exceptional circumstances for oncology drugs. Ludwig Boltzmann Society - Health Technology Assessment (2013). http://eprints.hta.lbg.ac.at/992/1
38. Carr DR, Anastasaki E, Bradshaw SE. Evaluating global early market access opportunities for innovative therapies: focus on Japan, UK and US. Value Health 18(3), A96 (2015).
39. European Medicines Agency launches adaptive licensing pilot project. EMA (2014). www.ema.europa.eu/ema
40. Bubela T, McCabe C, Archibald P et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen. Med. 10(7), 897-911 (2015).
41. Strategy of SAKIGAKE. MHLW (2015). www.mhlw.go.jp/english/policy
42. Hirschler B. Novartis to test new pricing model with heart failure drug. Reuters (2015). www.reuters.com/article
43. Kanavos P, Mills M. Options for the sustainable financing of innovative therapies. Presented at: LSE-ICL Forum on Medical Innovation Imperial College London, London, UK, 14 October 2015.
44. Wright B. The economics of intervention incentives: patents, prizes and research contracts. Am. Econ. Rev. 74(4), 691-707 (1983).
45. HE Institute/Galbraith Wight. Taking on the pharma pricing challenge: Two new approaches for affordability and access (2015). www.healtheconomics.com
46. Fund for rare diseases and orphan drugs. King Baudouin Foundation (2011). www.archipelkbs.org/fund
47. Belgium EUROPLAN national conference final report. EUCERD (2014). www.eucerd.eu/upload/file
48. Melchiorri D, Pani L, Gasparini P et al. Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat. Rev. Drug Discov. 12(9), 719 (2013).
49. Feltmate K, Janiszewski PM, Gingerich S, Cloutier M. Delayed access to treatments for rare diseases: who's to blame? Respirology 20(3), 361-369 (2015).
50. Fine JD. Inherited epidermolysis bullosa. Orphanet. J. Rare Dis. 5, 12 (2010).
51. Teen with epidermolysis bullosa (EB) gets to fulfill dreams. Global Genes (2015). https://globalgenes.org/raredaily
52. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB registry experience, 1986-2006. J. Am. Acad. Dermatol. 60(2), 203-211 (2009).
53. NHS. Epidermolysis bullosa - Kayla's story. NHS choices (2015). www.nhs.uk/Conditions/Epidermolysis-bullosa
54. Shinkuma S. Dystrophic epidermolysis bullosa: a review. Clin. Cosmet. Investig. Dermatol. 8, 275-284 (2015).
55. Cutlar L, Greiser U, Wang W. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa. Exp. Dermatol. 23(1), 1-6 (2014).